Urinary Retention: An Uncommon Adverse Effect of Venlafaxine

References (20)

1. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord. 1998;51(3):237–254. PubMed CrossRef
2. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol. 1996;16(suppl 2):54S–59S, discussion 59S–61S. PubMed CrossRef
3. Selvaraj V, Gunasekar P, Kumar S, et al. Urinary incontinence due to overactive detrusor muscle: a rare side effect of venlafaxine. Case Rep Urol. 2015;2015:690931. PubMed CrossRef
4. Polimeni G, Salvo F, Cutroneo P, et al. Venlafaxine-induced urinary incontinence resolved after switching to sertraline. Clin Neuropharmacol. 2005;28(5):247–248. PubMed CrossRef
5. Cavanaugh GL, Martin RE, Stenson MA, et al. Venlafaxine and urinary incontinence: possible association. Ann Pharmacother. 1997;31(3):372. PubMed CrossRef
6. Votolato NA, Stern S, Caputo RM. Serotonergic antidepressants and urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(6):386–388. PubMed CrossRef
7. Hansen LK. Venlafaxine-induced increase in urinary frequency in 3 women. J Clin Psychiatry. 2004;65(6):877–878. PubMed CrossRef
8. Inghilleri M, Conte A, Frasca V, et al. Venlafaxine and bladder function. Clin Neuropharmacol. 2005;28(6):270–273. PubMed CrossRef
9. Tuman TC. Venlafaxine-induced urinary retention. Prim Care Companion CNS Disord. 2021;23(1):20l02702. PubMed CrossRef
10. Demirdöğen ŞO, Yıldırım Demirdöğen E, Adanur Ş. Acute urinary retention after venlafaxine use. Arch Ital Urol Androl. 2017;89(2):160–161. PubMed CrossRef
11. Benazzi F. Urinary retention with venlafaxine‐fluoxetine combination. Hum Psychopharmacol. 1998;13(2):139–140. CrossRef
12. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). 1992.
13. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314, discussion 1314–1315. PubMed CrossRef
14. Norton PA, Zinner NR, Yalcin I, et al; Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol. 2002;187(1):40–48. PubMed CrossRef
15. Katofiasc MA, Nissen J, Audia JE, et al. Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Sci. 2002;71(11):1227–1236. PubMed CrossRef
16. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. PubMed CrossRef
17. Stahl SM. Personalized medicine, pharmacogenomics, and the practice of psychiatry: on the threshold of predictive therapeutics in psychopharmacology? CNS Spectr. 2008;13(2):115–118. PubMed CrossRef
18. Lenze EJ. Reversal of SSRI-associated urinary retention with mirtazapine augmentation. J Clin Psychopharmacol. 2012;32(3):434. PubMed CrossRef
19. Thor KB, Katofiasc MA, Danuser H, et al. The role of 5-HT(1A) receptors in control of lower urinary tract function in cats. Brain Res. 2002;946(2):290–297. PubMed CrossRef
20. Delbressine LP, Vos RM. The clinical relevance of preclinical data: mirtazapine, a model compound. J Clin Psychopharmacol. 1997;17(suppl 1):29S–33S. PubMed CrossRef